Discounted Cash Flow (DCF) Analysis Levered
BiondVax Pharmaceuticals Ltd. (BVXV)
$1.82
+0.01 (+0.55%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Projected | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 1.82 |
|---|---|
| Beta | 2.462 |
| Diluted Shares Outstanding | 10.75 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 15.53% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 15.432 |
| Total Debt | 69.74 |
| Total Equity | 19.56 |
| Total Capital | 89.30 |
| Debt Weighting | 78.09 |
| Equity Weighting | 21.91 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Projected | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | - | - | - | - | - |
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 15.51 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | 15.70 |
| Equity Value | - |
| Shares Outstanding | 10.75 |
| Equity Value Per Share | - |